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PHypertrophic Cardiomyopathy
Endocardial Radiofrequency Ablation for
Hypertrophic Obstructive Cardiomyopathy
Acute Results and 6 Months’ Follow-Up in 19 Patients
Thorsten Lawrenz, MD,*† Bianca Borchert, MD,* Christian Leuner, MD,* Markus Bartelsmeier, MD,*
Jens Reinhardt, MD,* Claudia Strunk-Mueller, MD,* Dorothee Meyer Zu Vilsendorf, MD,*
Marc Schloesser, MD,* Gerald Beer, MD,* Frank Lieder, MD,‡ Christoph Stellbrink, MD,*
Horst Kuhn, MD*
Bielefeld, Witten, and Münster, Germany
Objectives The purpose of this study was to examine the efficacy and safety of endocardial radiofrequency ablation of sep-
tal hypertrophy (ERASH) for left ventricular outflow tract (LVOT) gradient reduction in hypertrophic obstructive
cardiomyopathy (HOCM).
Background Anatomic variability of the vessels supplying the obstructing septal bulge can limit the efficacy of transcoronary
ablation of septal hypertrophy in HOCM. Previous studies showed that inducing a local contraction disorder with-
out reducing septal mass results in effective gradient reduction. We examined an alternative endocardial ap-
proach to transcoronary ablation of septal hypertrophy by using ERASH.
Methods Nineteen patients with HOCM were enrolled; in 9 patients, the left ventricular septum was ablated, and in 10
patients, the right ventricular septum was ablated. Follow-up examinations (echocardiography, 6-min walk test,
bicycle ergometry) were performed 3 days and 6 months after ERASH.
Results After 31.2  10 radiofrequency pulses, a significant and sustained LVOT gradient reduction could be achieved
(62% reduction of resting gradients and 60% reduction of provoked gradients, p  0.0001). The 6-min walking
distance increased significantly from 412.9  129 m to 471.2  139 m after 6 months, p  0.019); and New
York Heart Association functional class was improved from 3.0  0.0 to 1.6  0.7 (p  0.0001). Complete
atrioventricular block requiring permanent pacemaker implantation occurred in 4 patients (21%); 1 patient had
cardiac tamponade.
Conclusions ERASH is a new therapeutic option in the treatment of HOCM, allowing significant and sustained reduction of the
LVOT gradient as well as symptomatic improvement with acceptable safety by inducing a discrete septal con-
traction disorder. It may be suitable for patients not amenable to transcoronary ablation of septal hypertrophy or
myectomy. (J Am Coll Cardiol 2011;57:572–6) © 2011 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.07.055e
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vranscoronary ablation of septal hypertrophy (TASH) is an
ccepted option and alternative to surgery in patients with
ypertrophic obstructive cardiomyopathy (HOCM) (1–7).
owever, owing to variability of septal branch anatomy,
pproximately 5% to 8% of patients are not suitable for
ASH (4,5). Previous studies showed that inducing a local
eptal contraction disorder without reducing septal mass by
sing only small alcohol dosages for TASH results in
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ccepted July 13, 2010.ffective gradient reduction (8,9). Thus, we hypothesized
hat such localized contraction disorders could also be
nduced by endocardial radiofrequency (RF) ablation of
eptal hypertrophy (ERASH) in HOCM.
ethods
atients. We enrolled 19 patients (age 60.7  12 years)
ith typical HOCM and left ventricular outflow tract
LVOT) gradients of 50 mm Hg at rest or after provo-
ation and severe symptoms (New York Heart Association
NYHA] functional class III) despite adequate medication
n the study (Table 1); 8 patients were receiving beta-
lockers (162.5  52 mg metoprolol), and 11 patients,
erapamil (294.5  63 mg). In 1 patient (no. 8), dual-
hamber pacing for gradient reduction had been ineffective
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ad been ineffective (gradient reduction 50%). Reasons
or TASH inefficacy were either inadequate septal branch
natomy (6 of 8 patients), or a high spillover of contrast
edium into collateral branches (2 of 8 patients). Surgical
yectomy was offered to all patients with failed TASH;
nly patients refusing myectomy were enrolled in the study.
he study protocol was approved by the local ethics com-
ittee of the University of Muenster, Muenster, Germany.
ll patients gave written, informed consent to participate in
he study.
oninvasive measurements. Echocardiographic measure-
ents of the LVOT gradients were performed under resting
onditions and after provocation (bicycle exercise, 75 W, for
min) before ERASH, 3 days after ERASH, and at 6
onths of follow-up. At each follow-up, the 6-min walking
istance was measured twice on 2 separate days. Cardiac
agnetic resonance imaging (MRI) was performed in a
ubgroup of 5 randomly chosen patients (Figs. 1 and 2).
fter the procedure, continuous electrocardiographic mon-
toring was performed for 8 days.
nvasive measurements and ablation technique. The
VOT gradients at rest and post-extrasystolic were mea-
ured invasively. A catheter was placed at the bundle of His.
adiofrequency ablation was performed with a 4-mm
rrigated-tip ablation catheter (CoolFlow Irrigation Pump,
iosense Webster, Diamond Bar, California) 30 ml/min. In
he first 2 patients, left ventricle (LV) ablation was chosen
nder the assumption that the LV gradient reduction would
e best achievable by ablating the LV septal myocardium
10,11). Because of some catheter instability, a right ventri-
atient CharacteristicsTable 1 Patient Characteristics
Patient #
Age,
Yrs
Septal
Diameter,
mm
LVOT Gradient at
Rest at Baseline
(After ERASH)
1 53 26 100 (50)
2 72 20 140 (90)
3 45 28 100 (20)
4 50 30 120 (80)
5 78 20 80 (20)
6 81 20 120 (30)
7 62 22 80 (40)
8 66 20 140 (20)
9 79 21 100 (40)
10 47 18 120 (40)
11 47 16 60 (20)
12 41 25 20 (0)
13 56 27 100 (100)
14 64 24 100 (20)
15 67 18 40 (10)
16 53 24 120 (40)
17 59 22 20 (0)
18 59 21 20 (0)
19 72 25 80 (40)
Average 60.7 22.5 87.4 (34.7)RASH  endocardial radiofrequency ablation of septal hypertrophy; LV  left ventricle; LVOT  left venle (RV) approach was attempted
n the next 5 patients. With more
xperience, we again switched to
LV approach to test whether
hat could further improve the
fficacy of ERASH. The decision
egarding which approach to use
as then made on a case-by-case
asis for the remaining patients.
A retrograde transaortic ap-
roach was used for LV ablation,
n inferior caval approach for RV
blation; in 1 case, the LV sep-
um was ablated after trans-
eptal puncture.
We delivered RF current
trictly to the most proximal
arts of the septum in immediate
icinity to the LVOT. To pre-
ent induction of complete heart
lock, we navigated the tip of the ablation catheter as far as
ossible away from the His-bundle region, marked by the
lectrode catheter or additionally by a “tag” in the CARTO
Biosense Webster) map (Fig. 1). To produce a myocardial
efect comparable to that of TASH, we ablated a region of
pproximately 2 cm2 (Fig. 3). The therapeutic end point for
RASH was a gradient reduction of 50%.
tatistics. Statistical analysis was performed using com-
ercial software (SPSS version 10.0, SPSS, Chicago, Illinois).
aired data were analyzed with the Wilcoxon signed-
ank test; unpaired data were analyzed with the Mann-
Gradient After
ation at Baseline
fter ERASH)
Ablation
Site
No. RF
Pulses
Maximum Power,
W
200 (160) LV 20 40
260 (130) LV 14 40
200 (140) RV 40 40
200 (170) RV 40 50
200 (140) RV 26 50
240 (80) RV 26 50
200 (160) RV 37 50
200 (90) LV 25 50
200 (100) RV 13 50
180 (160) LV 38 50
160 (80) LV 35 50
140 (30) RV 30 50
200 (200) RV 38 50
240 (120) RV 50 70
100 (30) RV 22 70
220 (140) LV 35 70
160 (80) LV 30 70
140 (60) LV 44 70
140 (90) LV 30 70
88.4 (113.7) — 31.2 54.7
Abbreviations
and Acronyms
ERASH  endocardial
radiofrequency ablation of
septal hypertrophy
HOCM  hypertrophic
obstructive cardiomyopathy
LV  left ventricle
LVOT  left ventricular
outflow tract
MRI  magnetic resonance
imaging
NYHA  New York Heart
Association
RF  radiofrequency
RV  right ventricle
TASH  transcoronary
ablation of septal
hypertrophyLVOT
Provoc
(A
1tricular outflow tract; RF  radiofrequency; RV  right ventricle.
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ignificant. No corrections for multiple comparisons were
ade.
esults
total of 14 to 40 RF pulses (90 s, 40 to 70 W, procedure
ime 139 47 min) were delivered to either the RV septum
n  10) or the LV septum (n  9) (Table 1). Significant
levation of myocardial serum markers was noticeable in all
atients (Table 2). We observed a sustained reduction of
he LVOT gradient at rest (62%) or after provocation
60%) (Tables 3 and 4, Figs. 4 and 5). Only patients with
remaining resting gradient 50 mm Hg after ERASH
n  4) received their pre-procedural medication (vera-
amil or beta-blockers) at the time of hospital discharge.
After 6 months, NYHA functional class improved from
.0  0.0 to 1.6  0.7 (p  0.01); the 6-min walking
istance improved by 58 m (413  129 m at baseline;
58  108 m immediately after ERASH; 471  139 m
fter 6 months, p  0.019) (Fig. 6).
Gadolinium-contrast MRI exhibited a subaortic septal
one of late enhancement with a maximal penetration depth
Figure 1 3-Dimensional RV and LV Maps
Using the CARTO System With MRI Fusion
Three-dimensional picture of right ventricle (RV) and left ventricle (LV) maps
(blue) using the CARTO system with magnetic resonance imaging (MRI) fusion.
The pink points indicate the area of the bundle of His; the red points indicate
the ablation points. The “empty space” between the endocardial RV and LV
maps represents the thickened interventricular septum.f 28 mm (Fig. 2). Early after ERASH, this zone wasFigure 2 Gadolinium Contrast MRI After RV Septal ERASH
(Top) Gadolinium contrast MRI 3 days after RV septal endocardial radiofrequency
ablation of septal hypertrophy (ERASH). Distinct late enhancement with a low sig-
nal core is seen after 40 pulses (60 s, 50 W). (Bottom) After 6 months, there is
homogeneous late enhancement, similar to the result after transcoronary ablation
of septal hypertrophy (see Fig. 3). Abbreviations as in Figure 1.Figure 3 Gadolinium Contrast MRI 6 Months After Low-Dose TASH
Gadolinium contrast MRI 6 months after successful low-dose (0.7 ml ethanol)
transcoronary ablation of septal hypertrophy (TASH). The arrow indicates the zone
of late enhancement. Abbreviations as in Figure 1.
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nd a homogenous late enhancement after 6 months. There
as only a minor, albeit significant, reduction of the septal
iameter after 6 months compared with baseline (21.4 3.4
m vs. 22.6  3.7 mm, p  0.046), but both echocardi-
graphy and MRI showed a circumscribed region of re-
uced contraction at the ablation site (visual interpretation
f regional wall motion).
omplications. During RF ablation, complete heart block
ccurred in 4 patients with permanent pacemaker depen-
ency (patient nos. 2, 6, 11, and 14). All patients received a
ual-chamber pacemaker and were still pacemaker depen-
ent after 6 months. One patient (no. 6) had acute pericar-
ial tamponade during RV ablation caused by perforation of
he RV pacing lead, requiring surgical revision.
iscussion
atheter-based treatment of HOCM initially aimed for
eduction of septal myocardial mass to relieve LVOT
bstruction, and required injection of relatively large
mounts of ethanol (3 to 5 ml) (2–7). However, evidence
as grown that injection of smaller amounts of ethanol (1 to
ml) may be equally effective as higher dosages (8,9). Thus,
elief of obstruction may be more dependent on induction of
localized reduction in contractility responsible for the
ynamic obstruction. Early studies on the behavior of
VOT obstruction during temporary balloon occlusion of
eptal branches without alcohol injection by Gietzen et al.
12) support this hypothesis, as transient ischemia already
ed to an acute, reversible LVOT gradient reduction. The
resent study aimed to prove that endocardial RF ablation
ould create a myocardial scar comparable to that of a
low-dose” TASH procedure (Figs. 2 and 3). Although we
id not observe a significant reduction of septal mass after
RASH, gadolinium-contrast MRI showed a nearly trans-
ural scar, 2 cm deep in some patients (Fig. 2).
Our data indicate that ERASH is safe and effective in
educing LVOT gradients and resulted in a significant
eak Myocardial Enzyme Risefter Radiofrequency AblationTable 2 Pe k M ocard al Enzyme RiseAfter Radiofrequency Ablation
Myocardial
Enzyme
Total
Creatine
Kinase, U/l
Creatine Kinase-
MB Fraction,
U/l
Troponin I,
ng/ml
Lactate
Dehydrogenase,
U/l
Mean value 415.1 267 77.6  52 10.7  13 405.9 96
Normal range 145.0 10.0 0.08 248
radient Reduction During theherapeutic Session (p < 0.001)Table 3 Gradie t Reduction During theTherapeutic Session (p < 0.001)
Baseline
End of ERASH
Session
LVOT gradient at rest, mm Hg 87.4 39 34.7 29
LVOT gradient post-extrasystolic, mm Hg 188.4 40 113.7 47bbreviations as in Table 1.mprovement of exercise capacity and NYHA functional
lass after 6 months. Although our study does not indicate
significant difference in gradient reduction of a left-sided
ersus right-sided approach, our data do not yet allow a
ecommendation for which approach (LV vs. RV) should be
hosen.
Except for 1 case of pericardial tamponade, no severe
omplications occurred. The percentage of patients requir-
ng additional pacemaker implantation (21%) was similar to
hat of the early learning phase of TASH and about twice
hat expected after contemporary TASH treatment (1–9).
Comparing results of ERASH in this study to TASH or
yectomy, the extent of gradient reduction appears to be
ower after ERASH (3–9). In only 7 of 19 patients was a
esidual gradient 100 mm Hg after provocation achieved.
owever, the patients included in our study represent a
ubset of very severely affected patients with HOCM,
ncluding many with previously failed TASH attempts.
herefore, a comparison in terms of the effectiveness man-
ates further prospective investigations.
tudy limitations. It is a limitation that we did not measure
aximum oxygen consumption or additional echocardio-
Figure 4 Reduced LVOT Obstruction at Rest
Reduction of obstruction at rest is seen on continuous-wave Doppler echocardi-
ography. The left ventricular outflow tract (LVOT) gradients are shown (in mm
Hg) before, 3 days after, and 6 months after endocardial radiofrequency abla-
tion of septal hypertrophy (ERASH). p  0.001 for all.
ignificant Relief of ObstructionDoppler-Echocardiography, p < 0.001)nd Improvement f Exercise Capacityuring 6 Months f Follow-Up (p < .05)
Table 4
Significant Relief of Obstruction
(Doppler-Echocardiography, p < 0.001)
and Improvement of Exercise Capacity
During 6 Months of Follow-Up (p < 0.05)
Before
ERASH
3 Days After
ERASH
6 Months
After ERASH
LVOT gradient at rest, mm Hg 77.7 30 39.8 29 26.5 22
LVOT gradient after exercise,
mm Hg
157.5 37 89.1 42 64.2 44
NYHA functional class 3.0 2.6 1.6
Walking distance, 6-min
walking test, m
412.9 129 458.4 108 471.2 139
YHA  New York Heart Association; other abbreviations as in Table 1.
g
p
C
E
a
s
I
T
R
K
S
l
R
1
1
1
K
576 Lawrenz et al. JACC Vol. 57, No. 5, 2011
Endocardial Radiofrequency Ablation for HOCM February 1, 2011:572–6raphic parameters (diastolic function, systolic anterior motion
henomenon).
onclusions
ndocardial radiofrequency ablation of septal hypertrophy
llows significant and sustained gradient reduction and
ymptomatic improvement of patients with severe HOCM.
Figure 5 Reduced LVOT Obstruction After Provocation
Reduction of obstruction after provocation (75 W bicycle ergometry). The LVOT
gradients are shown (in mm Hg) before, 3 days after, and 6 months after
ERASH. p  0.0001 for all. Abbreviations as in Figure 4.
Figure 6 Improved 6-Min Walking Distance
Improvement of the 6-min walking distance is shown (in meters) before, 3 days
after, and 6 months after endocardial radiofrequency ablation of septal hypertro-
phy (ERASH). p  0.019.ht may be suitable for patients who are not suitable for
ASH or myectomy.
eprint requests and correspondence: Dr. Thorsten Lawrenz,
linikum Bielefeld, Department of Cardiology, Teutoburger
trasse 50, Bielefeld D-33604, Germany. E-mail: thorsten.
awrenz@sk-bielefeld.de.
EFERENCES
1. Maron BJ, McKenna WJ, Danielson GK, et al. Clinical expert
consensus document on hypertrophic cardiomyopathy: a report of the
American College of Cardiology Task Force on Clinical Expert
Consensus Documents and the European Society of Cardiology
Committee for Practice Guidelines. J Am Coll Cardiol 2003;42:
1687–713.
2. Sigwart U. Non-surgical myocardial reduction for hypertrophic ob-
structive cardiomyopathy. Lancet 1995;22:211–4.
3. Kuhn H, Gietzen FH, Schäfers M, et al. Changes in the left ventricular
outflow tract after transcoronary ablation of septal hypertrophy (TASH)
for hypertrophic obstructive cardiomyopathy as assessed by transoesoph-
ageal echocardiography and by measuring myocardial glucose utilization
and perfusion. Eur Heart J 1999;20:1808–17.
4. Kuhn H, Lawrenz T, Lieder F, et al. Survival after transcoronary ablation
of septal hypertrophy in hypertrophic obstructive cardiomyopathy
(TASH): a 10 year experience. Clin Res Cardiol 2008;97:234–43.
5. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D,
Seggewiss H. One-year follow-up of percutaneous septal ablation for
symptomatic hypertrophic obstructive cardiomyopathy in 312 patients:
predictors of hemodynamic and clinical response Clin Res Cardiol
2007;96:864–73.
6. Fernandes VL, Nielsen C, Nagueh SF, et al. Follow-up of alcohol
septal ablation for symptomatic hypertrophic obstructive cardiomyop-
athy the Baylor and Medical University of South Carolina experience
1996 to 2007. J Am Coll Cardiol Intv 2008;1:561–70.
7. Alam M, Dokainish H, Lakkis N. Alcohol septal ablation for
hypertrophic obstructive cardiomyopathy: a systematic review of pub-
lished studies. J Interv Cardiol 2006;19:319–27.
8. Veselka J, Zema´nek D, Tomasov P, Duchonova´ R, Linhartova´ K.
Alcohol septal ablation for obstructive hypertrophic cardiomyopathy:
ultra-low dose of alcohol (1 ml) is still effective. Heart Vessels
2009;24:27–31.
9. Veselka J, Duchonova´ R, Pa´lenı´ckova´ J, et al. Impact of ethanol dosing
on long-term outcome of alcohol septal ablation for obstructive
hypertrophic cardiomyopathy: a single-center, prospective, and ran-
domized study. Circ J 2006;70:1550–2.
0. Lawrenz T, Kuhn H. Endocardial radiofrequency ablation of septal
hypertrophy. A new catheter-based modality of gradient reduction in
hypertrophic obstructive cardiomyopathy. Z Kardiol 2004;93:493–9.
1. Emmel M, Sreeram N, deGiovanni JV, Brockmeier K. Radiofre-
quency catheter septal ablation for hypertrophic obstructive cardiomy-
opathy in childhood. Z Kardiol 2005;94:699–703.
2. Gietzen FH, Leuner C, Gerenkamp T, Kuhn H. Relief of obstruction
in hypertrophic cardiomyopathy by transient occlusion of the first
septal branch of the left coronary artery (abstr). Eur Heart J 1994;15
Suppl:125.
ey Words: alcohol ablation y catheter ablation y HOCM y
ypertrophic cardiomyopathy y radiofrequency ablation.
